A new clinical trial assessing the affects of stem cells in helping individuals suffering from degenerative spinal cord damage has shown promising results.
According to BrainStorm Cell Therapeutics, data from its ALS (Amyotrophic lateral sclerosis) Phase I/II human trial using NurOwn technology reveals the treatment to so far be proven safe.
Professor Dimitrios Karussis, who is leading the clinical trial at Hadassah Medical Center, said: "There have been no significant side effects in the initial patients we have treated with BrainStorm's NurOwn."
As a result, he claimed the stem cell technology may represent "the biggest hope" in the field of degenerative diseases such as ALS, which attack the nerve cells in the brain and spinal cord.
Following the review of the data from the first four patients, the trial has been granted permission to proceed with testing the therapy on more sufferers.
In 90 to 95 per cent of ALS cases the disease appears at random with no apparent connection to family history of the condition or associated risk factors, according to the National Institute of Neurological Disorders and Stroke.
News brought to you by Serious Law specialists in spinal injury
Posted by Paul Breen